Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myo-inositol in smokers with bronchial dysplasia
NCT00783705Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2008
- Primary completion
- May 2014
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of bCalm in bronchial dysplasia and lung cancer, sponsored by National Cancer Institute. Primary endpoint: Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Participant-specific Analysis at 6 months. Started Nov 2008; status: completed.
02
Drugs
bCalm
03
Conditions
bronchial dysplasialung cancer
Beyond the preview
Go deeper on NCT00783705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783705.